A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma
Sponsor: Tocagen Inc.
Terminated
Sponsor decision
Other terminated trials from Tocagen Inc.
More terminations from Tocagen Inc.
A PHASE1 clinical study on Bladder Cancer and Colorectal Cancer, this trial is terminated or withdrawn. The trial is conducted by Tocagen Inc. and has accumulated 12 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2020 — Mar 2020 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
▶ Show 7 earlier versions
-
Sep 2018 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tocagen Inc.
For direct contact, visit the study record on ClinicalTrials.gov .